It is currently Wed Jul 26, 2017 3:28 am

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Research 2006

Nothing new - but an interesting interview with the NMSS Head of Research.

The Rituximab results should certainly be of interest for those with progressive forms of MS.


http://skins.broadbandvideo.com/nmss/06 ... ipt_01.pdf

Ian
Read more : Research 2006 | Views : 1989 | Replies : 1


Clinical trials in MS

List from NMSS

The list looks very impressive, although the CRABs still appear too often for my liking. They, to me, represent the Model T Fords - they've had their day and now we want somthing akin to a Formula 1 racing car.

Interesting that Bone Marrow Transplanation studies appear to be on the rise, as do trials of some of the heavy duty chemo drugs. Surely, some on the list will deliver! (fingers crossed) ...
Read more : Clinical trials in MS | Views : 1741 | Replies : 0


SC12267

Here's a drug from German company 4SC AG.
http://www.dvcg.de/gb/news/portfolio_presse.asp?artikel=504

Martinsried – 4SC AG, a drug discovery and development company specialising in research and development of therapeutic agents, announced today that they have successfully concluded Phase I studies for the small molecule product candidate SC12267 for treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. A safe and well tolerated dose was determined in these studies, which did not cause any relevant side effects ...
Read more : SC12267 | Views : 1666 | Replies : 1


Apolioprotein E

I'm happy about anything that mentions neuroprotection..

: J Pharmacol Exp Ther. 2006 Jun 1; Links

Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis.

Li FQ, Sempowski GD, McKenna SE, Laskowitz DT, Colton CA, Vitek MP.

Division of Neurology, Department of Medicine, Duke University Medical Center.

Apolipoprotein E (apoE), well known to play a role in lipid transport and ...
Read more : Apolioprotein E | Views : 1430 | Replies : 0


Tovaxin anyone???

Hi everyone

Bromley had said that there was going to be a "poster presentation at the 2006 Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) at the San Francisco Marriott on June 3, 2006." That would be today :) . Does annyone have any info on that or is it too early for that?? What can I say, I am anxious. I am ...
Read more : Tovaxin anyone??? | Views : 3832 | Replies : 9


BHT 3009 research

Read more : BHT 3009 research | Views : 1922 | Replies : 1


Oral fumurate research

Read more : Oral fumurate research | Views : 2161 | Replies : 5


TGN1412

Parexel Drug Trial Had Shortfalls, U.K. Investigation Says

Parexel International Corp., which ran a clinical trial that left six men with multiple organ failure earlier this year, didn't have a doctor with adequate training and experience screening the patients, the U.K. health regulator said.

Parexel, based in Waltham, Massachusetts, failed to ensure that closely held German biotechnology company TeGenero AG, which developed the medicine, had proper insurance to cover the volunteers, the London-based Medicines ...
Read more : TGN1412 | Views : 1526 | Replies : 0


Synta

Dignan,

Trials not for MS, but something to keep in mind.

Ian


Synta launches human trials for anti-inflammatory drug

Synta Pharmaceuticals Corp. has launched two new midstage human clinical trials to test an anti-inflammatory drug.
The Lexington, Mass.-based private company said it had began dosing patients in two separate Phase II trials regarding the compound apilimod mesylate. One trial will focus on rheumatoid arthritis and the other will target common variable immunodeficiency, a condition ...
Read more : Synta | Views : 1481 | Replies : 0


Serum

Dignan,

I think the following can be moved from Phase I to Phase II.

Ian


Cambrex to Produce Serum for Trial

Cambrex to Make Serum for Merrimack Pharmaceuticals Autoimmune Disease Study.

Cambrex Corp. said Tuesday one of its subsidiaries will produce a serum for a Merrimack Pharmaceuticals clinical study on autoimmune disease treatments.

The subsidiary, Cambrex Bio Science Hopkinton Inc., will produce trial quantities of Merrimack's lead drug candidate, MM-093, for the Phase II ...
Read more : Serum | Views : 1744 | Replies : 1


 

Login  •  Register


Statistics

Total posts 238937 • Total topics 26054 • Total members 17319


Contact us | Terms of Service